Jilin Aodong Pharmaceutical Group Co., Ltd. specializes in the manufacturing and marketing of pharmaceutical products. Besides, the group offers food products. Net sales break down by activity as follows: - sale of pharmaceutical products (89.4%); - sale of food products (6.8%); - other (3.8%). All sales are in China.

Employees

5,050

Sector

Pharmaceuticals

Calendar

05:00am Ex-dividend date - 0.2 CNY

More about the company

Quotes

Date	Price	Change	Volume
22/10/26	CN¥16.82	-1.18%	7,389,012
21/10/26	CN¥17.02	0.00%	5,357,900
20/10/26	CN¥17.02	-1.22%	8,400,332
19/10/26	CN¥17.23	+0.76%	7,371,352
16/10/26	CN¥17.10	-0.29%	10,803,725

End-of-day quote Shenzhen S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Jilin Aodong Pharmaceutical Group Co., Ltd.

Company calendar

End-of-day quote Shenzhen S.E. 22/10/2026			5-day change	1st Jan Change
16.82 ^CNY	-1.18%		-1.92%	-13.88%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI

Market Cap	19.72B 2.95B 2.64B 2.43B 2.21B 4.15B 280B 4.21B 29.3B 11.54B 147B 11.09B 10.85B 464B	P/E 2024	13.1x	P/E 2025	9.57x
Enterprise Value	19B 2.85B 2.54B 2.34B 2.13B 3.99B 270B 4.05B 28.23B 11.12B 141B 10.68B 10.45B 447B	EV / Sales 2024	7.76x	EV / Sales 2025	9.49x
Free-Float	66.63%	Yield 2024	2.9%	Yield 2025	2.56%

10-15	Jilin Aodong Pharmaceutical Group Co., Ltd. Announces Interim Profit Distribution Plan for 2026 to Be Implemented (A Shares), payable on October 23, 2026	CI
08-31	Jilin Aodong Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for the First Half of 2026	CI
08-28	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-09	China Approves Aodong Subsidiary's Levocarnitine Injection	MT
05-21	Jilin Aodong Pharmaceutical Gets China Approval for Supplemental Registration of Heart Drug	MT
05-12	Jilin Aodong Pharmaceutical Group Co., Ltd. Approves Final Cash Dividend on A Shares for the Year 2025, Payable on 08 July 2026	CI
04-29	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-20	Jilin Aodong Pharmaceutical's Attributable Profit Jumps 54% in 2025	MT
04-17	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-13	Aodong Pharmaceutical's Subsidiary Gets Nod to Market 10 Traditional Chinese Medicines	MT
01-26	Beijing Sun-Novo Pharmaceutical Research Co., Ltd. cancelled the acquisition of Jiangsu Langyan Life Technology Holdings Co., Ltd. from Li Qian, Ganzhou Langyi Investment Center (Limited Partnership) and Other shareholders.	CI
30/10/25	Jilin Aodong Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
21/10/25	Aodong Pharmaceutical Gets China Supplementary Nod for Anti-Opioid Medication	MT

1 day	-1.18%
1 week	-1.92%
Current month	-3.39%
1 month	-5.35%
3 months	-8.14%
6 months	-7.23%
Current year	-13.88%

Jilin Aodong Pharmaceutical Group Co., Ltd. Share Price

Stocks

000623

CNE000000719

Pharmaceuticals

Valuation: Jilin Aodong Pharmaceutical Group Co., Ltd.

Chart: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest news: Jilin Aodong Pharmaceutical Group Co., Ltd.

Quotes and Performance

Price Extremes

Managers and Directors: Jilin Aodong Pharmaceutical Group Co., Ltd.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

1 week	16.79	17.28
1 month	16.79	17.76
Current year	16.36	20.93
1 year	16.36	22.08
3 years	12.49	22.08
5 years	12.49	22.08
10 years	12.49	29.43

Manager	Title	Age	Since
Shu Qin Guo CEO	Chief Executive Officer	63	16/07/2017
Kai Yang DFI	Director of Finance/CFO	49	30/04/2004
Shu Yuan Zhang DFI	Director of Finance/CFO	54	17/06/2007

Director	Title	Age	Since
Shu Qin Guo BRD	Director/Board Member	63	31/01/2000
Shu Yuan Zhang BRD	Director/Board Member	54	16/07/2020
Xiu Lin Li CHM	Chairman	74	17/05/2005

Date	Insider	Type	Main position	Quantity	% Market Cap.
25/11/25	An Ning Li	Buy		100	0.0000%
29/07/24	Xiu Lin Li	Buy	Chairman	350,000	0.0302%
29/07/24	Shu Qin Guo	Buy	Chief Executive Officer	320,000	0.0276%

	2024	2025
Net sales	2.61B 391M 349M 322M 293M 549M 37.04B 557M 3.88B 1.53B 19.41B 1.47B 1.44B 61.48B	2.34B 350M 312M 288M 262M 491M 33.13B 498M 3.47B 1.37B 17.36B 1.31B 1.28B 54.99B
Net income	1.55B 232M 207M 191M 174M 326M 22.01B 331M 2.31B 908M 11.53B 872M 854M 36.53B	2.4B 359M 320M 295M 268M 504M 33.99B 511M 3.56B 1.4B 17.81B 1.35B 1.32B 56.41B
Net Debt	-386M -57.81M -51.6M -47.61M -43.25M -81.14M -5.48B -82.39M -574M -226M -2.87B -217M -212M -9.09B	-724M -108M -96.8M -89.3M -81.14M -152M -10.27B -155M -1.08B -424M -5.38B -407M -398M -17.05B

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JILIN AODONG PHARMACEUTICAL GROUP CO., LTD.	-1.18%	-1.92%	-17.27%	+4.60%	2.95B
ELI LILLY AND COMPANY	+2.83%	+4.40%	+60.84%	+123.50%	1,165B
JOHNSON & JOHNSON	+3.81%	+5.66%	+38.70%	+74.91%	645B
ABBVIE INC.	+0.14%	+0.63%	+24.71%	+95.03%	504B
ROCHE HOLDING AG	+0.03%	+3.27%	+39.79%	+64.06%	380B
MERCK & CO., INC.	-1.76%	+1.41%	+68.06%	+43.41%	363B
NOVARTIS AG	+1.58%	+2.37%	+22.91%	+51.98%	297B
ASTRAZENECA PLC	+2.90%	+2.22%	+3.51%	+24.45%	269B
AMGEN INC.	+2.04%	+3.05%	+51.12%	+60.42%	237B
GILEAD SCIENCES, INC.	+2.36%	-0.11%	+29.42%	+102.04%	195B
Average	+1.46%	+1.81%	+32.18%	+64.44%	405.84B
Weighted average by Cap.	+1.98%	+2.59%	+42.79%	+82.90%